Federal Reversal on Fentanyl Test Strips Reshapes Harm Reduction Debate

A new federal policy shift is intensifying debate around harm reduction, overdose prevention, and the nation’s response to the fentanyl crisis. The Trump administration, through updated guidance from the Substance Abuse and Mental Health Services Administration, has ended the use of certain federal grant funds for fentanyl test strips and other substance test kits distributed for individual use, reversing prior federal support for these tools.

Fentanyl test strips have been widely used by community organizations and public health programs to help identify fentanyl and other dangerous adulterants in the illicit drug supply. Public health advocates and pharmacy leaders argue that the strips are a low-cost overdose prevention tool that can help people make safer decisions and reduce risk.

For healthcare leaders, pharmacists, policymakers, and addiction professionals, the funding reversal raises important questions about the future of harm reduction policy, community-based prevention strategies, and access to evidence-informed overdose prevention services. The change also signals a broader federal shift away from some harm reduction approaches, even as overdose prevention remains a top public health priority.